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Introduction: Dilated cardiomyopathy (DCM) is a frequent cause of heart failure and 25 
a common indication for heart transplantation. DCM has a strong genetic basis and 26 
the most common disease-causing mutations are variants that truncate the 27 
sarcomeric protein titin (TTN truncating variants (TTNtvs); prevalence in familial or 28 
idiopathic DCM 25%1 and 13%2, respectively). The prognosis of DCM is poor, but 29 
functional recovery from end-stage failure has been reported following both optimal 30 
medical therapy3 and left ventricular assist device (LVAD) support4,5, though the 31 
determinants of successful recovery are unknown. It has been proposed that 32 
recovery from genetic cardiomyopathy may not be expected since the underlying 33 
cause is irreversible; whereas recovery may be more likely when DCM is due to 34 
reversible, non-genetic factors (e.g. myocarditis)6. To address this directly, we 35 
sequenced TTN in end-stage DCM patients who either recovered or did not recover 36 
following LVAD support. 37 
 38 
Methods: We sequenced TTN in 70 cases referred to the Royal Brompton and 39 
Harefield National Health Service Trust between 1998 and 2010 for LVAD 40 
implantation due to non-ischaemic, medically refractory, end-stage DCM. Of these, 41 
29 patients recovered cardiac function during LVAD support and had their LVAD 42 
explanted. The other 41 patients did not recover cardiac function and were 43 
transplanted or died while on LVAD support. A pharmacological regime designed to 44 
promote recovery (combination therapy4,5) was used in 35/70 patients and 45 
continued after explantation. The study was approved by institutional ethics 46 
committees, with written informed consent from participants. Targeted next-47 
generation sequencing (NGS) was performed using an assay designed to assess all 48 
known coding exons in TTN2.  Genetic variants in NGS data were identified as 49 
previously described2 and were confirmed independently.  Statistical comparisons 50 
between groups were tested using Fisher's exact test, ANOVA and unpaired t-test as 51 
appropriate. Differences in survival rates were tested using the Mantel-Cox test. 52 
Statistical significance was defined as a P-value of <0.05. 53 
    54 
Results: We identified TTNtvs in 10 out of 70 cases (14% of total; Table 1). All TTNtvs 55 
were either novel or very rareαand located in exons constitutively expressed in the 56 
heart and, as such, considered disease-causing2. Of the patients with a TTNtv, 6/10 57 
recovered sufficient cardiac function to enable LVAD explanation. There was no 58 
statistical difference in TTNtv frequency between recovery cases and those who 59 
were transplanted or died on the device (6/29 [21%] vs. 4/41 [10%] respectively, 60 
P=0.30), and no evidence of clinical differences between TTNtv-positive and TTNtv-61 
negative cases at the time of LVAD implantation (Table 1). Comparing the transplant-62 
free survival rate in recovered patients, we found no difference between TTNtv-63 
positive and TTNtv-negative cases; at three years post-explant, 4/6 (67%) TTNtv-64 
positive cases were free from death and transplantation compared to 17/23 (74%) 65 
TTNtv-negative cases (Figure 1; P=0.74).  66 
 67 
Discussion: Sustained improvement in cardiac function is observed in end-stage 68 
DCM following medical therapy and LVAD support, but it was previously unknown 69 
whether recovery could be achieved in DCM due to a genetic cause.  Here, we show 70 
that recovery is possible in DCM due to a truncating mutation in the TTN gene. We 71 
also present the preliminary findings that DCM with a TTNtv is as equally recoverable 72 
as DCM without a TTNtv and that the long-term durability of recovery is also 73 
comparable. These observations now require replication in multi-centre prospective 74 
studies. Since TTNtvs are the most common genetic cause of DCM these results have 75 
important implications for patient selection for recovery programs.  76 
αNine TTNtvs were not present in ExAC, whilst one variant had a minor allele 77 
frequency of 0.0000166 (http://exac.broadinstitute.org/). 78 
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Table 1:  TTNtv status and clinical features of LVAD-supported, end-stage DCM 124 
patients who either recovered cardiac function and were successfully explanted 125 
(recovered), or who were transplanted or died with the device in situ (not 126 
recovered). 127 
 128 
 129 
Figure 1.  TTNtv and survival in recovered DCM patients. In the three years 130 
following successful LVAD explanation, the actuarial rate of survival and freedom 131 
from transplantation at 1, 2 and 3 years post-explant in TTNtv-positive cases was 132 
83%, 83% and 67%.  In TTNtv-negative cases, the rate was 88%, 88% and 75%.  133 
Differences between the survival rates were tested using the Mantel-Cox test. 134 
 135 
  136 
Table 1. 137 
 138 
 TTNtv, n=10 No TTNtv, n=60  
Variable Recovered Not recovered Recovered 
Not 
recovered P value 
Number of patients 6 4 23 37 0.30A
Male, n (%) 6 (100) 4 (100) 18 (78) 30 (81) 0.29A
Clinical comments - 1 post-chemo 2 PPCM 3 PPCM 2 post-chemo  
Family history, n (%) 2 (33) 0 (0) 2 (8.7) 1 (2.7) 1.0A 
Survived > 30 days post 
LVAD implant, n (%) 6 (100) 2 (50) 23 (100) 34 (92) 0.13
A 
Received combination 
therapy3, n (%) 6 (100) 2 (50) 23 (100) 14 (38) 0.69
A 
Age at diagnosis,  
mean (SD), years 31.7 (10.8) 37.3 (15.6) 31.6 (12.5) 34.5 (11.9) 0.77
B 
Age at implant,  
mean (SD), years 33.0 (12.2) 38.6 (17.3) 35.5 (12.8) 37.5 (12.8) 0.83
B 
Implant LVEF,  
mean (SD), % 25.6 (13.3) 19.7 (9.5) 20.8 (10.1) 18.8 (9.6) 0.58
B 
Implant FS,  
mean (SD), % 10.3 (4.6) 8.5 (3.4) 9.3 (3.9) 8.6 (4.2) 0.90
B 
Implant LVEDD,  
mean (SD), mm 69.8 (6.6) 72.3 (10.4) 73.1 (14.3) 71.7 (9.6) 0.95
B 
Time on LVAD,  
mean (SD), days 214 (125) 212 (313) 317 (151) 520 (532) 0.11
B 
Explant LVEF,  
mean (SD), % 64.0 (4.2) n/a 65.9 (9.5) n/a 0.64
C 
Explant FS,  
mean (SD), % 29.5 (3.3) n/a 31.9 (7.3) n/a 0.53
C 
Explant LVEDD,  
mean (SD), mm 44.5 (6.4) n/a 54.3 (8.9) n/a 0.05
C 
TTNtvs in cohort who recovered: c.87624C>A*; c.49346-1G>A*; c.76383_76386delTAAT*; 
c.46782C>A*; c.81518delC*; c.71326G>T. 
TTNtvs in cohort who did not recover: c.69976G>T; c.67495C>T*; c.41641C>T; c.58172delA*. 
Titin variant position is given according to locus reference genomic (LRG) sequence 391_t1. A detailed 
overview of TTN gene structure, including the isoforms and protein domains affected by the TTNtvs 
described here, can be found at http://cardiodb.org/titin. *Variants reported in Roberts et al2. P-values 
calculated with Fisher's exact testA, ANOVAB and unpaired t-testC. 
Abbreviations: TTNtv=titin truncating variant, LVAD=left ventricular assist device, DCM=dilated 
cardiomyopathy, PPCM=peri-partum cardiomyopathy, LVEF=left ventricular ejection fraction, 
FS=fractional shortening, LVEDD=left ventricular end diastolic dimension, n/a=not applicable. 
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